Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 242 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clostridial Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated No phase listed Observational

Small Bowel Transit Time in Clostridium Difficile Colitis

NCT01309750
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Small Bowel Transit Study
Radiation
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

NCT07221370
View directory record Official record
Conditions
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Interventions
Vancomycin 125mg, Placebo
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

NCT00871117
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
11
States / cities
Antioch, California • Daly City, California • Hayward, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

NCT03466502
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin
Drug
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

NCT00772343
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile Infection
Interventions
0.9% Normal Saline, Clostridium difficile toxoid vaccine, Clostridium difficile toxoid vaccine with adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Tampa, Florida • Marietta, Georgia • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

NCT00214461
View directory record Official record
Conditions
Clostridium Infections
Interventions
Vaccine diluent buffer (Placebo), C. difficile toxoid vaccine (2 µg), C. difficile toxoid vaccine (10 µg), C. difficile toxoid vaccine (50 µg)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Orlando, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

NCT00346073
View directory record Official record
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Boostrix™, ADACEL®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 64 Years
Enrollment
2,337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

NCT01629589
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 12 Years
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
8
States / cities
Sacramento, California • Bardstown, Kentucky • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

NCT02692651
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
Fidaxomicin, Vancomycin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Probiotics for Clostridium Difficile Infection in Older Adults

NCT01680874
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Withdrawn Phase 4 Interventional

Fidaxomicin to Prevent Clostridium Difficile Colonization

NCT01552668
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fidaxomicin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Phase 2 Interventional

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
AZD5148, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Phoenix, Arizona • Chula Vista, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed No phase listed Observational

Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection

NCT02326636
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

NCT00467519
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 1 Interventional

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

NCT04891965
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
ART24, Placebo
Biological · Drug
Lead sponsor
Adiso Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Clearwater, Florida • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)

NCT01716533
View directory record Official record
Conditions
Infections, Clostridium Difficile
Interventions
Blood sampling, Stool sample collection
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Little Rock, Arkansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

NCT02437487
View directory record Official record
Conditions
Clostridium Difficile
Interventions
SER-109, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Oceanside, California • Sacramento, California • Ventura, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Specific Carbohydrate Diet for Clostridium Difficile

NCT03925636
View directory record Official record
Conditions
Clostridium Difficile Infection, Diet Modification
Interventions
Specific Carbohydrate Diet
Dietary Supplement
Lead sponsor
David Suskind
Other
Eligibility
18 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

NCT01439165
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine, Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
31
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

NCT02563106
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Infections
Interventions
SYN-004, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Torrance, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jun 10, 2026, 6:15 PM EDT
Completed No phase listed Observational

A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients

NCT02497417
View directory record Official record
Conditions
Gastroenteritis, Infectious Colitis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Jun 10, 2026, 6:15 PM EDT